When the Iron Dome Chooses Not to Engage
The Iron Dome is an air-defense system designed to intercept incoming rockets.
But an equally important part of the system is knowing when not to engage.
When a rocket is detected, the Iron Dome does more than register that a threat is approaching. It calculates its trajectory and estimates where it is likely to land. If the rocket threatens a populated area or critical infrastructure, an interceptor can be launched. If it is expected to fall harmlessly in an open area, the system may allow it to fall.
That is not inaction. It is a calculated decision.
Interceptors are costly and finite. Launching one against every detected rocket would consume a scarce resource without necessarily changing the outcome. The system therefore has to decide which threats actually require engagement.
There may be a lesson here for drug discovery and development.
Biomedical research continually identifies potential drug targets, compounds, combinations and therapeutic approaches.
But identifying a scientific opportunity is not the same as deciding to engage with that opportunity and turn it into a development program.
Every program consumes scarce resources: scientific expertise, capital, clinical trial capacity, patients and, above all, time. Those resources have to be allocated among competing opportunities.
So the difficult question is not simply: Can we pursue this?
It is: Should we engage?
That requires reading the trajectory.
As a program advances, evidence begins to reveal where it may be heading. Does the underlying biology remain convincing? Does the drug reach and engage its target as intended? Can an effective dose be given safely? Are early clinical results meaningful? Is there still a realistic path toward a medicine that improves patient care?
Drug-development trajectories, of course, are not as predictable as the physical trajectory of a rocket. They can change as new evidence emerges, biomarkers refine patient selection or development strategies evolve. But that makes continual reassessment of the evidence more important, not less.
Sometimes the trajectory supports further investment. Sometimes it tells us that the better decision is to disengage and ultimately terminate the program.
That second decision can be remarkably difficult.
Years of scientific work, substantial investment and personal commitment can make disengaging from a program feel like failure. But resources already spent cannot change where the evidence says a program is heading.
The Iron Dome operates on a simple principle.
Detection alone does not require engagement.
Trajectory matters. Consequence matters. Resources matter.
Drug development needs the same discipline.
Not every potential target should become a drug program. Not every program warrants another trial. And not everything we are capable of pursuing deserves further investment.
Sometimes choosing not to engage or choosing to disengage is itself the right decision.
The Iron Dome does not engage every rocket it detects.
Perhaps drug development should not engage every opportunity it discovers.
